Eczematous dermatitis comprises a heterogeneous group of inflammatory skin diseases characterized by a typical morphological reaction pattern. In the acute stage, the typical clinical features include itching, redness, papules, and vesicles associated with exudation. The two most frequent reasons for an eczematous reaction are atopic dermatitis (AD) and allergic contact dermatitis (ACD). Although AD and ACD are completely different in nature and pathogenetically unrelated, both disorders in the acute stage share common morphological features, especially vesicle formation, which ultimately causes a disruption of the epidermal barrier. The loss of this protective shield allows additional external noxious agents of microbial, chemical, or physical origin to enter the skin and to aggravate and to perpetuate the disease. Hence, vesicle formation and subsequent loss of the epidermal barrier is a key event in acute eczematous reactions.

Histopathologically, eczematous reactions are characterized by a mononuclear infiltrate with an intercellular epidermal edema, a condition called spongiosis. Severe spongiosis causes keratinocytes’ intercellular attachments to rupture and is regarded as the major culprit in generating vesicles in acute eczematous dermatitis (1). In this issue of the JCI, however, Trautmann et al. (2) provide evidence that another pathway, induction of apoptosis of keratinocytes via activation of the Fas receptor system, also disrupts the epidermal barrier, and they argue that infiltrating T lymphocytes. Fas and its ligand are essential for normal homeostasis of the lymphoid system, as seen when defects in the Fas system result in lymphadeno-pathy, splenomegaly, or autoimmunity (7). This pathway is also implicated in the progression of tumors, since tumor cells that express high levels of FasL have been shown to escape an immune response by killing Fas-bearing lymphocytes (8). The paper by Trautmann et al. (2) now identifies the keratinocyte as an additional target of Fas-induced apoptosis and provides evidence that this form of cell death contributes to the pathogenesis of eczematous dermatitis. Keratinocytes normally express low levels of Fas, but IFN-γ upregulates Fas on these cells (9, 10). The authors show that cultured keratinocytes are driven into apoptosis upon coinoculation with autologous activated T lymphocytes. Addition of a blocking Fas-Fc fragment inhibited apoptosis, indicating that keratinocyte death is due to triggering of the Fas system. Secretion of IFN-γ by T lymphocytes, which promotes Fas upregulation in keratinocytes, is a crucial early step in this pathway. Therefore, in this case keratinocyte apoptosis occurs only in association with an inflammatory reaction; but it is important to mention that the inflammatory infiltrate is not the consequence but the cause of apoptosis. A similar mechanism may apply to hepatitis B virus–related liver cirrhosis, where T lymphocytes kill hepatocytes using the Fas system (11). In Hashimoto’s thyroiditis, the inflammatory mediator IL-1β seems to be the initiator of thyrocyte death by upregulating Fas on these cells (5).

Fas-mediated keratinocyte death recently has been shown to be involved in another dermatosis, toxic epidermal necrolysis (TEN) (12). TEN is a life-threatening drug-induced cutaneous reaction with extensive epidermal destruction. Unlike in AD and ACD, in TEN keratinocytes kill themselves by

No eczema without keratinocyte death

Thomas Schwarz
Ludwig Boltzmann Institute for Cell Biology and Immunobiology of the Skin, Department of Dermatology, University Münster, Von-Esmarchstrasse 56, D-48149 Münster, Germany.
Phone: 49-251-8356565; Fax: 49-251-8358579; E-mail: schwtho@uni-muenster.de.
expressing FasL, and thus do not need the help of lymphocytes. Although the mechanism for upregulation of the killer ligand is unknown, inhibition of the Fas pathway by application of neutralizing Fas antibodies appears to be a promising therapeutic approach (12).

Clinical implications of keratinocyte apoptosis

From the pathophysiologic point of view, it is interesting that the same mechanism is demonstrated in AD and ACD, since these dermatoses are usually regarded as mutually exclusive, AD being a classic example of a T-helper 2–mediated (Th2-mediated) and ACD of a Th1-mediated process (13). Th2 cells preferentially release IL-4, IL-5, and IL-10 but not IFN-γ. Since IFN-γ promotes a Th1 response, IFN-γ has even been applied therapeutically in AD, unfortunately not with great success (14). However, Grewe et al. recently suggested that Th2 cells are important only in the initial stage of AD and that a shift toward a Th1 response occurs later and leads to high expression of IFN-γ in lesions (15). These authors speculated that IFN-γ expression via upregulation of the adhesion molecule ICAM-1 contributes to the subsequent accumulation of inflammatory cells. Consistent with this suggestion, the present findings (2) imply that the high expression of IFN-γ also propagates the inflammatory process via disruption of the epidermal barrier. Interestingly, in histologic sections of AD and ACD lesions alike, the majority of apoptotic keratinocytes were found not in spongiotic regions, but in areas that retained normal cohesion of epidermal cells. Hence, one can speculate that apoptosis precedes spongiosis and, further, that apoptotic death of keratinocytes promotes spongiosis by enabling the influx of extracellular fluid into the epidermis.

ACD has always been regarded as a Th1-driven immune response, and the crucial role of the Th1 cytokine IFN-γ, especially during the induction (sensitization) phase, remains undisputed (16). The findings of Trautmann et al. (2) indicate an additional role for this cytokine in inducing keratinocyte cell death during the manifestation (elicitation) phase of this disease. Interestingly, ACD responds favorably to phototherapy with ultraviolet-B radiation (UVB). Although the mechanism remains unclear, we have observed that UVB can block the biological effects of IFN-γ by inhibiting the phosphorylation of the STAT1 protein (17). STAT1, which is critically involved in the signal transduction pathway of IFN-γ, must be tyrosine-phosphorylated to become active. In light of the present findings (2) that IFN-γ is crucial for manifesting ACD, it may be that UVB improves ACD through its inhibitory effect on IFN-γ signaling.

Another established treatment for both AD and ACD is the application of immunosuppressive drugs, such as steroids or cyclosporin A, which primarily target inflammatory cells (14). These drugs are very effective but are associated with side effects, so there is great demand for alternative therapeutic concepts. Here, too, the observations of Trautmann et al. (2) may be of value. One of the major factors perpetuating eczematous dermatitis is the disruption of the epidermal barrier. If, as proposed, Fas-mediated apoptosis of keratinocytes is the key event in this process, pharmacologic inhibitors of apoptosis should be of benefit. Such drugs would also be promising candidates to treat other disorders involving excess apoptosis, such as Alzheimer's disease, cerebral stroke, and acute hepatic failure.